Now Playing
Opinion|Videos|April 23, 2024
How Often Do Patients with ASCVD Achieve Target LDL-C?
A panel of clinical pharmacists introduce themselves and discuss how LDL cholesterol target achievement compares with guideline goals for patients with ASCVD who are treated with maximally tolerated statin monotherapy.
Advertisement
Episodes in this series
Advertisement
Related to this article
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
4
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
5